Poorer Survival in Stage III Early-Onset Colorectal Cancer

Combined data from 6 clinical trials show worse outcomes for patients with early-onset versus later-onset CRC, particularly among those with stage III disease.

Colorectal cancer is increasing in younger patients, without obvious cause. Retrospective series suggest a worse outcome in younger patients, which may be stage dependent. Investigators for the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) database report characteristics and outcomes for patients with early-onset (age <50 years) colorectal cancer (EO-CRC) compared with later-onset CRC (LO-CRC).

Of 16,349 patients enrolled in 6 clinical trials comparing 3 versus 6 months of adjuvant therapy, 1564 (9.6%) had EO-CRC. Patients with EO-CRC less often were male, more often had ECOG Performance Status of 0, and more often had distal primary tumors. A higher percentage of patients with EO-CRC than LO-CRC completed 6 months of the…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Poorer Survival in Stage III Early-Onset Colorectal Cancer

Topics

Reviewing Author